- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07540572
성인 진행성 고형암 환자를 대상으로 한 IDE574 요법의 안전성, 약동학 및 예비 효능에 관한 연구
An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.
연구 개요
상세 설명
Part 1 - Monotherapy Dose Escalation and Expansion:
Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.
Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.
Part 1C - Exploratory Food Effect Sub-study
Part 2 - Combination Dose Escalation and Expansion
Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.
Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: IDEAYA Clinical Trials
- 전화번호: +1-855-433-224
- 이메일: IDEAYAClinicalTrials@ideayabio.com
연구 장소
-
-
K'alak'i T'bilisi
-
Batumi, K'alak'i T'bilisi, 그루지야, 6000
- 모병
- High Technology Hospital MedCenter Ltd
-
수석 연구원:
- Tamta Makharadze, MD
-
연락하다:
- Mamuka Sikharulidze
- 전화번호: +995 568 999 559
- 이메일: sikharulidzemamuka3@gmail.com
-
Tbilisi, K'alak'i T'bilisi, 그루지야, 114
- 모병
- Pineo Medical Ecosystem
-
연락하다:
- Nino Kekenadze
- 전화번호: +995 593 660 940
- 이메일: Nkekenadze@pineo.ge
-
수석 연구원:
- Mziuri Zakaraia, MD
-
Tbilisi, K'alak'i T'bilisi, 그루지야, 112
- 모집하지 않고 적극적으로
- LLC ARENSIA Exploratory Medicine
-
Tbilisi, K'alak'i T'bilisi, 그루지야, 144
- 모집하지 않고 적극적으로
- Geo Hospitals Multiprofile Medical Center Tbilisi
-
Tbilisi, K'alak'i T'bilisi, 그루지야, 186
- 모집하지 않고 적극적으로
- LLC Caucasus Medical Centre
-
-
-
-
California
-
Santa Monica, California, 미국, 90404-2095
- 모집하지 않고 적극적으로
- UCLA - Parkside Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06510-3206
- 모병
- Yale School of Medicine - Cedar Street
-
수석 연구원:
- Patricia LoRusso, MD
-
연락하다:
- Karen Seely
- 전화번호: 203-314-3303
- 이메일: karen.rodriguezvasquez@yale.edu
-
-
Florida
-
Plantation, Florida, 미국, 33322
- 모병
- Florida Clinical Trials Group
-
수석 연구원:
- Harshad Amin, MD
-
연락하다:
- Sandra Perez
- 전화번호: 772-297-3057
- 이메일: perezs@floridactg.com
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322-1013
- 모병
- Winship Cancer Institute, Emory University
-
수석 연구원:
- Shipra Gandhi, MD
-
연락하다:
- Alejandra Bono
- 전화번호: 404-778-0954
- 이메일: alejandra.maria.bono@emory.edu
-
-
Missouri
-
St Louis, Missouri, 미국, 63110-1010
- 모병
- Washington University - Siteman Cancer Center
-
수석 연구원:
- Faisal Fa'ak, MD
-
연락하다:
- Pamela Coe
- 전화번호: 314-747-7569
- 이메일: mpamela@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, 미국, 08816
- 모병
- START Astera, LLC
-
수석 연구원:
- Bruno Fang, MD
-
연락하다:
- Bruno S Fang
- 전화번호: 732-426-4750
- 이메일: info@startresearch.com
-
-
New York
-
Lake Success, New York, 미국, 11042
- 모병
- START New York Long Island, LLC
-
수석 연구원:
- Geraldine O'Sullivan Coyne, MD
-
연락하다:
- Geraldine O'Sullivan Coyne
- 전화번호: 363-207-5160
- 이메일: g.osullivancoyne@startresearch.com
-
New York, New York, 미국, 10032-3729
- 모집하지 않고 적극적으로
- Columbia University Medical Center -161 Fort Washington
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- 모병
- SCRI Oncology Partners - PPDS
-
수석 연구원:
- Sarah Premji, MD
-
연락하다:
- Connor Frost
- 전화번호: 615-478-3475
- 이메일: connor.frost@scri.com
-
-
Texas
-
Austin, Texas, 미국, 78758
- 모병
- NEXT Texas LLC - Austin
-
수석 연구원:
- Sheena Sahota, MD
-
연락하다:
- Heather Watson
- 전화번호: 737-610-5202
- 이메일: nxtaus_coordinators@nextoncology.com
-
Dallas, Texas, 미국, 75039
- 모병
- NEXT Texas LLC - Dallas
-
수석 연구원:
- Faran Polani, MD
-
연락하다:
- Carmen Gonzalez
- 전화번호: 210-580-9479
- 이메일: NXTDFW_Coordinators@nextoncology.com
-
Fort Worth, Texas, 미국, 76104
- 모병
- START Dallas Fort Worth, LLC
-
수석 연구원:
- Henry Xiong, MD
-
연락하다:
- Henry Xiong
- 전화번호: 682-350-3010
- 이메일: info@startresearch.com
-
Houston, Texas, 미국, 77030-4009
- 모병
- MD Anderson Cancer Center
-
수석 연구원:
- Timothy Yap, MD
-
연락하다:
- Desirae Dufner
- 전화번호: 713-524-3434
- 이메일: DDufner@mdanderson.org
-
Houston, Texas, 미국, 77054
- 모병
- NEXT Texas LLC - Houston
-
수석 연구원:
- Jennifer Segar, MD
-
연락하다:
- Carmen Gonzalez
- 전화번호: 210-580-9479
- 이메일: nxthou_coordinators@nextoncology.com
-
San Antonio, Texas, 미국, 78229
- 모병
- NEXT Texas LLC - San Antonio
-
수석 연구원:
- David Sommerhalder, MD
-
연락하다:
- April Guerra
- 전화번호: 210-580-9500
- 이메일: NXTSA_Coordinators@nextoncology.com
-
San Antonio, Texas, 미국, 78229
- 모병
- Start San Antonio, LLC
-
수석 연구원:
- Amita Patnaik, MD
-
연락하다:
- Hector Navarro
- 전화번호: 210-593-5700
- 이메일: Hector.Navarro@startresearch.com
-
-
Utah
-
West Valley City, Utah, 미국, 84119
- 모병
- START Mountain Region, LLC
-
수석 연구원:
- William McKean, MD
-
연락하다:
- William B McKean
- 전화번호: 1 (801) 907-4750
- 이메일: info@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- 모병
- NEXT Virginia
-
수석 연구원:
- Mohamad Salkeni, MD
-
연락하다:
- Maybelle De La Rosa
- 전화번호: 703-783-4518
- 이메일: nxtvir_coordinators@nextoncology.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Archival Tissue sample for testing
- Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
- Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
- Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
- Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
- Have adequate bone marrow, renal and liver function.
- Life expectancy of >3 months
- Able to safely administer and retain orally administered study treatment
- Able to comply with contraceptive/barrier requirements
Key Exclusion Criteria:
- Known symptomatic brain metastases or leptomeningeal metastasis
- Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
- Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
- Have active liver or biliary disease.
- Have active, uncontrolled bacterial, fungal, or viral infection
- Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
- If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
- Prior irradiation to >25% of the bone marrow.
- Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Monotherapy Dose Escalation (Part 1A)
Participants with the appropriate tumor types will be treated with escalating doses of IDE574 |
IDE574 |
|
실험적: Monotherapy Dose Expansion (Part 1B)
Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574 |
IDE574 |
|
실험적: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant
Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant |
IDE574 Fulvestrant Injection |
|
실험적: Combination Dose Expansion (Part 2B)
Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant |
IDE574 Fulvestrant Injection |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
기간: Following the first dose of IDE574
|
incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0 |
Following the first dose of IDE574
|
|
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
기간: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
기간: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
기간: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
기간: total study duration
|
Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
기간: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
기간: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
기간: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
기간: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
기간: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
기간: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
기간: total study duration
|
total study duration
|
|
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
기간: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
기간: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
기간: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
기간: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
기간: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
기간: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
기간: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
기간: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
기간: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
기간: total study duration
|
total study duration
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- IDE574-001
- 178299 (기타 식별자: Regulatory Agency Identifier Number (s))
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .